Leerink Partnrs Has Strong Estimate for Certara Q1 Earnings

Certara, Inc. (NASDAQ:CERT - Free Report) - Investment analysts at Leerink Partnrs lifted their Q1 2025 EPS estimates for shares of Certara in a note issued to investors on Monday, April 14th. Leerink Partnrs analyst M. Cherny now anticipates that the company will earn $0.07 per share for the quarter, up from their prior estimate of $0.05. The consensus estimate for Certara's current full-year earnings is $0.28 per share.

Several other research firms have also recently weighed in on CERT. TD Cowen initiated coverage on Certara in a report on Thursday, February 27th. They set a "buy" rating and a $16.00 price target for the company. Barclays decreased their price target on shares of Certara from $13.00 to $11.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 10th. William Blair reissued a "market perform" rating on shares of Certara in a report on Thursday, February 27th. KeyCorp lifted their price target on shares of Certara from $15.00 to $18.00 and gave the company an "overweight" rating in a research report on Wednesday. Finally, Robert W. Baird raised their price objective on Certara from $9.00 to $13.00 and gave the stock a "neutral" rating in a research note on Friday, April 11th. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $15.17.

Certara Stock Performance

Shares of NASDAQ:CERT traded up $0.62 during trading on Wednesday, reaching $14.15. 2,114,112 shares of the stock were exchanged, compared to its average volume of 1,188,632. Certara has a 12 month low of $8.64 and a 12 month high of $17.94. The stock has a 50-day moving average price of $11.62 and a 200-day moving average price of $11.46. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The firm has a market cap of $2.28 billion, a PE ratio of -70.75, a PEG ratio of 9.29 and a beta of 1.64.

Institutional Investors Weigh In On Certara

Hedge funds have recently made changes to their positions in the stock. Blue Trust Inc. increased its position in Certara by 20.9% during the 4th quarter. Blue Trust Inc. now owns 4,747 shares of the company's stock worth $56,000 after purchasing an additional 822 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Certara by 3.6% during the fourth quarter. The Manufacturers Life Insurance Company now owns 23,720 shares of the company's stock worth $253,000 after buying an additional 823 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Certara by 48.4% during the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock valued at $34,000 after acquiring an additional 1,047 shares in the last quarter. Bank of Montreal Can grew its position in Certara by 9.1% during the 4th quarter. Bank of Montreal Can now owns 19,943 shares of the company's stock worth $212,000 after acquiring an additional 1,670 shares during the last quarter. Finally, Versant Capital Management Inc increased its holdings in Certara by 218.8% in the 1st quarter. Versant Capital Management Inc now owns 2,719 shares of the company's stock worth $27,000 after purchasing an additional 1,866 shares in the last quarter. 73.96% of the stock is currently owned by institutional investors and hedge funds.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.